ActiQs
Mer att utforska

Verktyg för dig

Combinations My watchlist

För professionella

Ämnesregister Source registry API & data
ActiQs / Research
PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för carfilzomib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

16 hits
Bibliografisk träff 2012-07-05

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2012.183
Bibliografisk träff 2012-06-04

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2012-04-422683
Bibliografisk träff 2012-05-29

Proteasome inhibitors in multiple myeloma: 10 years later.

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL.

Blood · research support, non-u.s. gov't; review-article; review; evaluation study; journal article · DOI 10.1182/blood-2012-04-403733
Bibliografisk träff 2012-05-03

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1182/blood-2012-03-414359
Bibliografisk träff 2012-01-10

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.

J Pharmacol Exp Ther · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1124/jpet.111.187542